Inflammation
Lp(a) carries over 85% of oxidized phospholipids in human plasma, a foundational mechanistic study (J Lipid Res 2008)
Original title: A novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma
This study tested whether Lp(a) is the preferential carrier of oxidized phospholipids (OxPL) in human plasma, using antibody E06 to detect the phosphocholine headgroup of oxidized apoB-100-bound phospholipids. Immunoprecipitation with an apo(a)-specific antibody showed more than 85% of E06 reactivity (OxPL) coimmunoprecipitated with Lp(a), and ultracentrifugation confirmed nearly all OxPLs were found in apo(a)-containing fractions rather than other apolipoproteins. In vitro transfer studies showed oxidized LDL preferentially donates OxPLs to Lp(a) over LDL in a time- and temperature-dependent manner, and about 50% of E06 immunoreactivity could be extracted from isolated Lp(a) using lipid solvents. The findings establish Lp(a) as the preferential carrier of phosphocholine-containing OxPL in human plasma, offering new insight into its physiological function and atherogenic mechanisms.
Original abstract
Oxidized phospholipids (OxPLs) on apolipoprotein B-100 (apoB-100) particles are strongly associated with lipoprotein [a] (Lp[a]). In this study, we evaluated whether Lp[a] is preferentially the carrier of OxPL in human plasma. The content of OxPL on apoB-100 particles was measured with monoclonal antibody E06, which recognizes the phosphocholine (PC) headgroup of oxidized but not native phospholipids. To assess whether OxPLs were preferentially bound by Lp[a] as opposed to other lipoproteins, immunoprecipitation and ultracentrifugation experiments, in vitro transfer studies, and chemiluminescent ELISAs were performed. Immunoprecipitation of Lp[a] from human plasma with an apolipoprotein [a] (apo[a])-specific antibody demonstrated that more than 85% of E06 reactivity (i.e., OxPL) coimmunoprecipitated with Lp[a]. Ultracentrifugation experiments showed that nearly all OxPLs were found in fractions containing apo[a], as opposed to other apolipoproteins. In vitro transfer studies showed that oxidized LDL preferentially donates OxPLs to Lp[a], as opposed to LDL, in a time- and temperature-dependent manner, even in aqueous buffer. Approximately 50% of E06 immunoreactivity could be extracted from isolated Lp[a] following exposure of plasma to various lipid solvents. These data demonstrate that Lp[a] is the preferential carrier of PC-containing OxPL in human plasma. This unique property of Lp[a] suggests novel insights into its physiological function and mechanisms of atherogenicity.
Summary written by lp-a.org from the published abstract; figures as published. Page updated 18 August 2026. Methods.